Cathie Wood's Ark Investment Management has deemed CRISPR/Cas 9 genome editing as "biotech's breakthrough of the century." Back in 2018, Ark identified this gene-editing tool as a potential $2 trillion-a-year opportunity, thanks to its potential to disrupt the treatment of 10,000 monogenic human diseases, aquaculture, and medical diagnostics.

After a dramatic sell-off in CRISPR/Cas 9 gene-editing stocks during the 2022 bear market, Wood's flagship fund has been steadily buying shares of Intellia Therapeutics (NASDAQ: NTLA) in 2023. Intellia is the second most advanced CRISPR/Cas9 player among the space's small contingent of publicly traded companies. 

Image Source: Getty Images.

Continue reading

Source Fool.com